We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Biochip Diagnoses Sepsis in Blood Samples

By LabMedica International staff writers
Posted on 28 Dec 2011
A new biochip will enable physicians to analyze blood for sepsis without having to send the sample to a central laboratory. More...


The more quickly and directly doctors recognize and treat sepsis, the greater the patient's chances of survival and speed can save lives especially in the case of blood poisoning.

A biochip device developed by scientists at the Fraunhofer Institute for Physical Measurement Techniques, (IPM; Freiburg, Germany) prepares the blood sample by separating the red blood cells from the blood and the plasma that remains is guided onto the biochip. In patients, who are suffering from sepsis, their immune system reacts by producing certain proteins. There are antibodies positioned on the chip, which fit these proteins as a key fits a lock. If the proteins are present in the blood, the antibodies fish them out of the fluid and bind them to the chip.

The apparatus distinguishes many tiny illuminated dots that show the protein was in the blood. If the patient is healthy, however, the chip remains dark. The scientists can even test for different proteins at the same time in one cycle. This is done by placing various different catcher molecules on the chip, to which specific molecules in the blood attach themselves. An ingenious selection of proven protein markers allows the investigators to obtain additional important information about the severity and cause of the illness.

Together with colleagues from a university hospital, the scientists have already successfully tested prototypes of the device and biochip. Each biochip can only be used once so they have to be affordable. Albrecht Brandenburg, PhD, a professor and group manager at IPM, said, "We predict that in the long run, with production on a large enough scale, each chip will cost no more than one euro. There are various possible applications: other conditions such as heart attacks or cancers can also be investigated in this way. What's more, the chip facilitates doping and urine testing."

Related Links:

Fraunhofer Institute for Physical Measurement Techniques



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Platelet Function Analyzer
PL-12
Automatic CLIA Analyzer
Shine i6000
New
Silver Member
Connectivity Solution
EKF Link
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: Schematic overview of the CRISPR-Assisted Nanodroplet-pairing Platform for Differential Identification of NTM (CANDI). The platform combines broad-range amplification using conserved regions of the 16S and 23S rRNA genes with species-specific CRISPR recognition. Fluorescence-coded CRISPR droplets are paired with sample droplets containing amplified products, enabling multiplexed target recognition and signal decoding (Image Credit: Yiwen Yang, Jingsong Xu, Dakang Xu)

Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification

Mycobacterial infections are difficult to diagnose because closely related species can have different clinical and therapeutic implications. Nontuberculous mycobacteria (NTM) are increasingly recognized... Read more

Industry

view channel
Image: TruVerus is designed to deliver a broad menu of routine blood tests from a small blood sample on a single, automated benchtop platform (Photo courtesy of Truvian Health)

Collaboration Advances Automated Benchtop Platform for Routine Blood Testing

Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.